Saturday, March 30, 2024

Cancer, Royalty, and Minding One's Business

›
I've been thinking about cancer a lot lately. That's no surprise. There hasn't been a day in 16+ years that I haven't though...
Tuesday, March 26, 2024

FDA Denies Approval for Bispecific (For Now)

›
The FDA has denied approval for the bispecific Odronextamab -- for now . In giving the denial, the FDA pointed to problems in the trial, rat...
Wednesday, March 20, 2024

Drug Name Tournament

›
Here's a kind of fun item for you Cancer Nerds: the website Fierce Pharma is holding a "drug name tournament" for the next fe...
Thursday, March 14, 2024

A Follow-Up on Secondary Cancers and CAR-T

›
 A follow-up to the news from a few months ago that the FDA was issuing a warning about CAR-T causing secondary cancers. After reports of pa...
Friday, March 8, 2024

New FDA Approval for R/R Follicular Lymphoma

›
Yesterday, the FDA granted accelerated approval for the combination of Zanubrutinib and Obinutuzumab for Relaped/Refractory Follicular Lymp...
2 comments:
Sunday, March 3, 2024

Will the FDA Change the Way They Approve Treatments?

›
The website BioSpace posted a really interesting article a coupe of weeks ago called " How Will FDA’s Pivot to Overall Survival Affect...
3 comments:
Tuesday, February 27, 2024

Epcoritamab Gets FDA Priority Review

›
A quick bit of news: The FDA granted Priority Review status to Epcoritamab for Relapsed/Refractory Follicular Lymphoma. Epcoritamab is a bi...